Robert A. Freedman

206-389-4524
rfreedman@fenwick.com
Partner
Corporate

Robert A.
Freedman

Robert A.
Freedman

Robert A.
Freedman

Partner
Corporate

Leveraging decades of experience, Rob provides a wide range of corporate and securities legal services to innovative late-stage and public companies in the life sciences and technology industries. He represents issuers and underwriters in going public transactions, including IPOs, de-SPACs, reverse mergers and direct listings, and in follow-on offerings and private placements of equity and debt securities. Rob previously co-chaired Fenwick’s Public Company and Capital Markets practice.

[Rob] has the ability to find a solution in any difficult situation and he offers great guidance."

Chambers USA, Client Quote

2023 Edition

Rob advises boards and management as an outside general counsel on day-to-day corporate and securities matters, including ’34 Act and public company reporting, corporate governance, and stock exchange rules.

Rob regularly helps clients strategize capital raising efforts, navigate risk, and tell a story through filings and disclosures over the long term. He represented Loxo Oncology in its IPO, follow-on offerings and its $8 billion acquisition by Eli Lilly and DICE Therapeutics in its IPO, follow-on offerings and $2.4 billion sale to Eli Lilly. He also represented DexCom, Day One Biopharmaceuticals, Morphic Holding, Prelude Therapeutics, and Third Harmonic Bio in their respective IPOs and subsequent follow-on offerings. Rob is committed to a company’s myriad legal needs through its full lifecycle.

Ranked as a top capital markets lawyer by Chambers USA, Chambers Global and Legal 500, and a preeminent life sciences practitioner by LMG Life Sciences, Rob is regularly sought after for his thought leadership. He is a lead author of the firm’s Technology and Life Sciences IPO Survey and co-chaired Practising Law Institute’s How to Prepare an Initial Public Offering annual program for several years.

Read more

  • Aeglea BioTherapeutics
  • Aceragen
  • AnaptysBio
  • Audentes Therapeutics
  • Augmedix
  • Castlight Health
  • Corium International
  • Day One Biopharmaceuticals
  • Dermira
  • Dexcom
  • DICE Therapeutics
  • Elevation Oncology
  • Graybug Vision
  • KalVista
  • Loxo Oncology
  • Morphic Holding
  • Neoleukin Therapeutics
  • Nurix Therapeutics
  • Obalon Therapeutics
  • Passage Bio
  • Prelude Therapeutics
  • Sema4
  • ServiceNow
  • Shutterfly
  • Sierra Oncology
  • Silver Spring Networks
  • Stoke Therapeutics
  • Sutro Biopharma
  • Third Harmonic Bio
  • Upwork

  • Aeglea BioTherapeutics
  • Aceragen
  • AnaptysBio
  • Audentes Therapeutics
  • Augmedix
  • Castlight Health
  • Corium International
  • Day One Biopharmaceuticals
  • Dermira
  • Dexcom
  • DICE Therapeutics
  • Elevation Oncology
  • Graybug Vision
  • KalVista
  • Loxo Oncology
  • Morphic Holding
  • Neoleukin Therapeutics
  • Nurix Therapeutics
  • Obalon Therapeutics
  • Passage Bio
  • Prelude Therapeutics
  • Sema4
  • ServiceNow
  • Shutterfly
  • Sierra Oncology
  • Silver Spring Networks
  • Stoke Therapeutics
  • Sutro Biopharma
  • Third Harmonic Bio
  • Upwork

  • Loxo Oncology in its $8B acquisition by Lilly
  • Aceragen in its merger with Idera Pharmaceuticals
  • Alpine Immune Sciences in its $4.9B acquisition by Vertex Pharmaceuticals
  • Augmedix in its private placement and reverse merger with Malo Holdings Corp.
  • Castlight Health in its $370M acquisition by Vera Whole Health
  • Corium in its $504M acquisition by Gurnet Point Capital
  • DICE Therapeutics in its $2.4 billion acquisition by Eli Lilly
  • Graybug Vision in its merger with CalciMedica
  • KalVista Pharmaceuticals in its merger with Carbylan Therapeutics
  • Neoleukin Therapeutics in its reverse merger with Neurogene
  • OncoGenex Pharmaceuticals in its merger with Achieve Life Science
  • Sema4 in its combination agreement with CM Life Sciences SPAC
  • Data Domain in its $2.4B acquisition by EMC
  • Cisco Systems in its $3.2B acquisition of WebEx Communications
  • Macromedia in its $3.4B merger with Adobe
  • Zappos.com in its $847M acquisition by Amazon.com

  • Loxo Oncology in its $8B acquisition by Lilly
  • Aceragen in its merger with Idera Pharmaceuticals
  • Alpine Immune Sciences in its $4.9B acquisition by Vertex Pharmaceuticals
  • Augmedix in its private placement and reverse merger with Malo Holdings Corp.
  • Castlight Health in its $370M acquisition by Vera Whole Health
  • Corium in its $504M acquisition by Gurnet Point Capital
  • DICE Therapeutics in its $2.4 billion acquisition by Eli Lilly
  • Graybug Vision in its merger with CalciMedica
  • KalVista Pharmaceuticals in its merger with Carbylan Therapeutics
  • Neoleukin Therapeutics in its reverse merger with Neurogene
  • OncoGenex Pharmaceuticals in its merger with Achieve Life Science
  • Sema4 in its combination agreement with CM Life Sciences SPAC
  • Data Domain in its $2.4B acquisition by EMC
  • Cisco Systems in its $3.2B acquisition of WebEx Communications
  • Macromedia in its $3.4B merger with Adobe
  • Zappos.com in its $847M acquisition by Amazon.com

Recognition Recognition Recognition

Recognition Recognition Recognition

Recognition
Chambers Global and Chambers USA

2020-2024

Chambers USA ranked Rob as a top lawyer in Capital Markets: Debt & Equity in California and the Western United States.

U.S. News - Best Lawyers

2019-2021

Named Rob "Lawyer of the Year" in corporate law (2020), and recognized him among “The Best Lawyers in America” for his work in corporate law, and securities and capital markets law (2019 – 2021).

The Legal 500

2022-2023

Highlighted among the United States’ leading lawyers for capital markets and healthcare: life sciences work.

LMG Life Sciences

2019

Recognized Rob as a Star.

  • Chambers USA recognized Rob as a leading lawyer in capital markets in California (2022)
  • Chambers USA ranked Rob as a top capital markets lawyer nationwide (2019 – 2022)
  • US News recognized Rob for his excellence in securities and capital markets law and corporate law (2019)
  • The Legal 500 recognized Rob for his capital markets practice (2016 – 2020)

Recognition
Chambers Global and Chambers USA

2020-2024

Chambers USA ranked Rob as a top lawyer in Capital Markets: Debt & Equity in California and the Western United States.

U.S. News - Best Lawyers

2019-2021

Named Rob "Lawyer of the Year" in corporate law (2020), and recognized him among “The Best Lawyers in America” for his work in corporate law, and securities and capital markets law (2019 – 2021).

The Legal 500

2022-2023

Highlighted among the United States’ leading lawyers for capital markets and healthcare: life sciences work.

LMG Life Sciences

2019

Recognized Rob as a Star.